YS Biopharma YS inventory is falling Monday after the corporate introduced PIKA recombinant COVID-19 vaccine.

YS Biopharma introduced interim Section 2 security and immunogenicity knowledge for its PIKA recombinant COVID-19 Vaccine. 

The interim knowledge have been from the Section 2 a part of the Section 2/3 head-to-head medical research to guage PIKA recombinant COVID-19 vaccine vs. inactivated COVID-19 vaccine. 

The interim knowledge evaluation of the Section 2 research offered that the trial met each major and secondary endpoints, measured by geometric imply titers (GMTs) of neutralizing antibody in opposition to Omicron virus and by seroconversion charges on Day 7 and Day 14 publish a booster dose administration.

The continuing Section 2/3 research was carried out within the Philippines and United Arab Emirates, which completed the enrollment of 300 and 5656 topics for the Section 2 and three trials, respectively. 

A booster dose of PIKA recombinant COVID-19 vaccine in individuals who had beforehand obtained two or extra doses of the inactivated COVID-19 vaccine elicited superior neutralizing immune responses in opposition to the Omicron virus to the responses in individuals receiving a booster dose of the inactivated COVID-19 vaccine. 

The variations of a number of folds of GMTs have been noticed with a 95% confidence interval of neutralizing antibodies in opposition to the Omicron virus. 

Value Motion: YS shares are down 35.30% at $3.10 on the final test Monday.